Compass Therapeutics (NASDAQ: CMPX) insider transactions
In the twelve months to 10 November 2026, executives and directors of Compass Therapeutics reported 0 open-market sales and 2 open-market purchases of 22,500 shares ($21,250), by 1 person, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 1 October 2026 | Lerner Neil | Chief Accounting Officer | Open-market purchase | +20,000 | $0.92 | 420,000 | Form 4 |
| 24 September 2026 | Lerner Neil | Chief Accounting Officer | Open-market purchase | +2,500 | $1.14 | 400,000 | Form 4 |
| 29 April 2026 | Lerner Neil | Chief Accounting Officer | Grant or award | +15,000 | $1.89 | 397,500 | Form 4 |
| 29 April 2026 | Anderman Jonathan | General Counsel | Grant or award | +25,000 | $1.89 | 196,000 | Form 4 |
| 8 February 2026 | Schuetz Thomas J. | Chief Executive Officer | Shares withheld for tax | −36,687 | $6.52 | 6,603,336 | Form 4 |
| 9 January 2026 | Schuetz Thomas J. | Chief Executive Officer | Shares withheld for tax | −46,777 | $5.35 | 6,640,023 | Form 4 |
| 2 January 2026 | Anderman Jonathan | General Counsel | Grant or award | +150,000 | $5.17 | 171,000 | Form 4 |
| 2 January 2026 | Lerner Neil | Chief Accounting Officer | Grant or award | +62,500 | $5.17 | 382,500 | Form 4 |
| 2 January 2026 | Schuetz Thomas J. | CEO | Grant or award | +250,000 | $5.17 | 6,686,800 | Form 4 |
| 2 January 2026 | Shin Barry | CFO | Grant or award | +125,000 | $5.17 | 525,000 | Form 4 |
| 16 November 2025 | Schuetz Thomas J. | Chief Executive Officer | Shares withheld for tax | −44,025 | $4.83 | 6,436,800 | Form 4 |
| 27 May 2025 | Schuetz Thomas J. | Chief Executive Officer | Open-market purchase | +10,000 | $2.11 | 6,480,825 | Form 4 |
| 9 April 2025 | OrbiMed Capital GP VI LLC | Director | Open-market sale | −3,571,428 | $1.59 | 0 | Form 4 |
| 9 April 2025 | Gordon Carl L | Director | Open-market sale | −3,571,428 | $1.59 | 0 | Form 4 |
| 7 April 2025 | Lerner Neil | Chief Accounting Officer | Open-market purchase | +20,000 | $1.42 | 320,000 | Form 4 |
| 7 April 2025 | Anderman Jonathan | Gen Counsel & Corporate Sec | Open-market purchase | +20,000 | $1.54 | 21,000 | Form 4 |
| 8 February 2025 | Schuetz Thomas J. | CEO | Shares withheld for tax | −41,687 | $3.50 | 6,470,825 | Form 4 |
| 9 January 2025 | Schuetz Thomas J. | CEO | Shares withheld for tax | −58,054 | $1.86 | 6,512,512 | Form 4 |
| 9 December 2024 | Shin Barry | CFO | Grant or award | +400,000 | $1.65 | 400,000 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Compass Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.